Major developments in the 2016 european guidelines for heart failure.
The European Society of Cardiology has recently published new guidelines on the diagnosis and treatment of acute and chronic heart failure (HF). This article aims to review these recommendations and their level of scientific evidence and to present the most innovative aspects. The most significant deviations from the 2012 edition are: 1) the introduction of the concept of HF with midrange LVEF (40-49%); 2) a new diagnostic algorithm for chronic HF, initially considering the clinical probability; 3) recommendations on preventing or delaying the apparition of HF; 4) indications for the use of the new sacubitril-valsartan compound, the first angiotensin receptor blocker and neprilysin inhibitor; 5) modification of indications for cardiac resynchronisation therapy; and 6) a new algorithm for a combined diagnostic and treatment strategy for acute HF based on the presence or absence of congestion and hypoperfusion.
Servicio de Medicina Interna, Hospital de Olot, Girona, España; Departament de Ciències Mèdiques, Universitat de Girona, Girona, España; Grupo de Insuficiencia Cardiaca y Fibrilación Auricular de la Sociedad Española de Medicina Interna. Electronic address: jctv5153@comg.cat.
J C
JC
Trullàs
Unidad de Insuficiencia Cardiaca de Medicina Interna y Programa UMIPIC, Hospital Universitario Central de Asturias, Oviedo, España; Grupo de Insuficiencia Cardiaca y Fibrilación Auricular de la Sociedad Española de Medicina Interna.
Á
Á
González-Franco
Clinical guidelines; Evidence-based Medicine; Guías clínicas; Heart Failure; Insuficiencia cardiaca; Medicina basada en la evidencia